Progressing cancers lose their differentiation, and acquire multiple genomic aberrations treatment resistance, what can be enhanced by tumor necrosis factor (TNF). Yet, T cell-based cancer immune therapies, require interferon (IFN)-γ TNF producing type I cells, to induce regression stable remission from metastatic disease. We therefore analyzed the effect of IFN-γ cells on phenotypic cell in en...

The cytokine interferon gamma (IFN-γ) and doxorubicin mono-therapy has been approved by the Food Drug Administration (FDA) for treatment of tumors. importance IFN-γ in immune system lies its immunomodulatory effects, antitumor therapy inhibiting RNA DNA synthesis. In this work, role activity combination with was investigated. Meanwhile, used as a vehicle to load over immunotherapy chemotherapy ...

Interferons (IFN) are subdivided into type I IFN (IFN-I, here synonymous with IFN-α/β), type II (IFN-γ) and type III IFN (IFN-III/IFN-λ) that reprogram nuclear gene expression through STATs 1 and 2 by forming STAT1 dimers (mainly IFN-γ) or the ISGF3 complex, a STAT1-STAT2-IRF9 heterotrimer (IFN-I and IFN-III). Dominant IFN activities in the immune system are to protect cells from viral replicat...

Background: Several factors have been related to response to pegylated interferon (PEG-IFN) in chronic hepatitis B (CHB). The occurrence of anti-IFN antibodies is associated with non-response to PEG-IFN in chronic hepatitis C. This study investigated the association between anti-IFN antibodies and response to PEG-IFN in CHB. Methods: Presence of anti-IFN antibodies was assessed at baseline and ...

The first STAT-containing transcription factor to be studied, the alpha-interferon-induced ISGF3, is composed of a Stat1:2 heterodimer and a weak DNA-binding protein, p48, that is a member of a growing family of proteins similar to the so-called interferon regulatory factor (IRF-1). The p48 and Stat1:2 heterodimer do not associate stably in the absence of DNA, but we show that amino acids appro...